<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02549469</url>
  </required_header>
  <id_info>
    <org_study_id>12656</org_study_id>
    <nct_id>NCT02549469</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily</brief_title>
  <official_title>A Pilot Four-Way Crossover Bioequivalence Trial of Sustained Release Forms of Naproxen Versus Aleve Tablets in Healthy Adult Subjects in a Fasted State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence trial in healthy adult subjects to determine the bioavailability of 3
      different sustained release formulations of naproxen 660 mg relative to the established
      commercial Aleve 220 mg tablet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum plasma concentration) for naproxen sodium</measure>
    <time_frame>Days 0, 1, 2, and 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 (partial area under the curve ) for naproxen sodium</measure>
    <time_frame>Days 0, 1, 2, and 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t (areas under the curve ) for naproxen sodium</measure>
    <time_frame>Days 0, 1, 2, and 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ (area under the curve) for naproxen sodium</measure>
    <time_frame>Days 0, 1, 2, and 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (The first time point where Cmax is reached) for naproxen sodium</measure>
    <time_frame>Days 0, 1, 2, and 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-8 (partial area under the curve) for naproxen sodium</measure>
    <time_frame>Days 0, 1, 2, and 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC8-16 (partial area under the curve ) for naproxen sodium</measure>
    <time_frame>Days 0, 1, 2, and 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC16-24 (partial area under the curve) for naproxen sodium</measure>
    <time_frame>Days 0, 1, 2, and 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz (terminal elimination rate constant)</measure>
    <time_frame>Days 0, 1, 2, and 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (terminal half life)</measure>
    <time_frame>Days 0, 1, 2, and 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) collection</measure>
    <time_frame>up to 50 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (SAEs) collection</measure>
    <time_frame>up to 50 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: sitting blood pressure</measure>
    <time_frame>up to 50 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs: repiratory rate</measure>
    <time_frame>up to 50 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs : pulse rate</measure>
    <time_frame>up to 50 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory data</measure>
    <time_frame>up to 50 days</time_frame>
    <description>Blood and urine samples were collected according to standard medical guidelines at the Screening Visit. In addition, hematology and chemistry were obtained at the end of the study (EOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination findings</measure>
    <time_frame>up to 50 days</time_frame>
    <description>Brief physical examination, including height, weight and BMI, was performed at the Screening Visit and at EOS</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Naproxen sodium extended release 660 mg, 20% HPMC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve (Naproxen sodium) 220 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen sodium extended release 660 mg, 30% HPMC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen sodium extended release 660 mg, 40% HPMC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen sodium 220 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bioequivalence in healthy adult subjects in a fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium ER (BAY117031), 20% HPMC</intervention_name>
    <description>1 tablet 660 mg administered orally once daily</description>
    <arm_group_label>Naproxen sodium extended release 660 mg, 20% HPMC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium ER (BAY117031), 30% HPMC</intervention_name>
    <description>1 tablet 660 mg administered orally once daily</description>
    <arm_group_label>Naproxen sodium extended release 660 mg, 30% HPMC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium ER (BAY117031), 40% HPMC</intervention_name>
    <description>1 tablet 660 mg administered orally once daily</description>
    <arm_group_label>Naproxen sodium extended release 660 mg, 40% HPMC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aleve (Naproxen Sodium, BAY117031)</intervention_name>
    <description>1 tablet 220 mg administered orally three times daily</description>
    <arm_group_label>Naproxen sodium 220 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy ambulatory male and female subjects 18 to 55 years of age, inclusive

          -  Body Mass Index (BMI) of approximately 18.0 to 30.0 kg/m2, and a total body weight &gt;50
             kg (110 lbs)

          -  Results of screening and clinical laboratory tests are within normal limits or
             considered not clinically significant by the Principal Investigator or Sponsor

          -  Female subjects of childbearing potential must be using a medically acceptable form of
             birth control for at least 1 month prior to screening (3 months on oral
             contraceptives), e.g., oral or patch contraceptives, intrauterine device,
             intramuscular injection or double-barrier and have a negative pregnancy test at
             Screening and on Day 0 of each treatment period. Female subjects of nonchildbearing
             potential must be amenorrheic for at least 2 years or had a hysterectomy and/or
             bilateral oophorectomy.

          -  Provide a personally signed and dated informed consent prior to inclusion in the trial
             indicating that the subject has been informed of all pertinent aspects of the trial.

        Exclusion Criteria:

          -  History of hypersensitivity to aspirin (ASA), naproxen sodium, or acetaminophen, and
             similar pharmacological agents or components of the products

          -  History of gastrointestinal bleeding or perforation, including bleeding related to
             previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two
             or more distinct episodes of proven ulceration or bleeding).

          -  Have taken ASA, ASA-containing products, acetaminophen (acetyl-para-amino-phenol or
             APAP) or any other NSAID (OTC or prescription) 7 days prior to dosing or during the
             treatment period, other than study treatment

          -  Loss of blood in excess of 500 mL within 56 days of the first dose of trial treatment
             (e.g., donation, plasmapheresis, or injury)

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing)

          -  Positive alcohol or drug screen at Screening or on Day 0 of Treatment Periods 1 or 2

          -  Females who are pregnant or lactating

          -  Smokers or currently consuming any type of tobacco product(s) including any smoking
             cessation nicotine-containing product (eg, nicotine patch, nicotine gum).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>September 11, 2015</last_update_submitted>
  <last_update_submitted_qc>September 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

